MDP Medexus Pharmaceuticals Inc
- 1.600
- -0.020-1.23%
Medexus Pharmaceuticals Inc News
With A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well?
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Met
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Ill
Medexus Pharmaceuticals Inc Price Target Cut to C$2.35/Share From C$2.85 by Stifel Nicolaus
Medexus Pharmaceuticals Inc Price Target Cut to C$2.35/Share From C$2.85 by Stifel Nicolaus
Medexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85
Stifel GMP on Friday reiterated its speculative-buy rating on the shares of Medexus Pharmaceuticals (MDP.TO) after lowering its price target to C$2.85 from C$3.50 after the company reported weaker tha
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results
Medexus Pharmaceuticals Inc. (MDP.TO) overnight Wednesday reported its Q3 2024 results. The company announced adjusted net loss of $0.53 million, compared with adjusted loss of $0.9 million, last year
Medexus Announces Fiscal Q3 2024 Results
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024T
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Feb
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine
Medexus Pharmaceuticals Inc. (MDP.TO) said Monday that Health Canada agreed to review the company's new drug submission for terbinafine hydrochloride nail lacquer to treat fungal nail infections. Mede
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million
Boasting A 23% Return On Equity, Is Medexus Pharmaceuticals Inc. (TSE:MDP) A Top Quality Stock?
Medexus Pharmaceuticals Inc (MDP) Receives a Buy From Bloom Burton
Stifel Nicolaus Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Echelon Wealth Partners Sticks to Their Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Medexus Schedules Second Fiscal Quarter 2024 Conference Call
Medexus Pharmaceuticals Inc. Is Maintained at Outperform by Raymond James
Medexus Pharmaceuticals Inc. Is Maintained at Outperform by Raymond James
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed b
Medexus Fully Repays Convertible Debentures In Cash At Maturity
